Merops Switch to
Peptidases

Inhibitor

Family Clan Small-molecule
inhibitor SEARCHES BLAST
MEROPS

Other
information

Literature for alogliptin (S09.003 inhibitor)

Summary Literature Inhibits

(Topics flags: I Inhibitor, V Review. To select only the references relevant to a single topic, click the link above. See explanation.)

    2018
  1. Naseef,H., Moqadi,R. and Qurt,M.
    Development and validation of an HPLC method for determination of antidiabetic drug alogliptin benzoate in bulk and tablets
    J Anal Methods Chem (2018) 2018, 1902510-1902510. PubMed  Europe PubMed DOI  PMC  EPMC  I
  2. Zhang,X., Zhang,Z., Yang,Y., Suo,Y., Liu,R., Qiu,J., Zhao,Y., Jiang,N., Liu,C., Tse,G., Li,G. and Liu,T.
    Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits
    Cardiovasc Diabetol (2018) 17, 160-160. PubMed  Europe PubMed DOI  PMC  EPMC  I
    3. 2016
  3. Arulmozhiraja,S., Matsuo,N., Ishitsubo,E., Okazaki,S., Shimano,H. and Tokiwa,H.
    Comparative binding analysis of dipeptidyl peptidase IV (DPP-4) with antidiabetic drugs - an ab initio fragment molecular orbital study
    PLoS ONE (2016) 11, e0166275-e0166275. PubMed  Europe PubMed DOI  I
  4. Mita,T., Katakami,N., Yoshii,H., Onuma,T., Kaneto,H., Osonoi,T., Shiraiwa,T., Kosugi,K., Umayahara,Y., Yamamoto,T., Yokoyama,H., Kuribayashi,N., Jinnouchi,H., Gosho,M., Shimomura,I. and Watada,H.
    Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A)
    Diabetes Care (2016) 39, 139-148. PubMed  Europe PubMed DOI  I
  5. Yabe,D. and Seino,Y.
    Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation
    Expert Opin Drug Saf (2016) 15, 249-264. PubMed  Europe PubMed DOI  I
  6. Yisireyili,M., Takeshita,K., Hayashi,M., Wu,H., Uchida,Y., Yamamoto,K., Kikuchi,R., Hao,C.N., Nakayama,T., Cheng,X.W., Matsushita,T., Nakamura,S. and Murohara,T.
    Dipeptidyl peptidase- IV inhibitor alogliptin improves stress-induced insulin resistance and prothrombotic state in a murine model
    Psychoneuroendocrinology (2016) 73, 186-195. PubMed  Europe PubMed DOI  I
    7. 2015
  7. Akita,K., Isoda,K., Shimada,K. and Daida,H.
    Dipeptidyl-peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice
    J Am Heart Assoc (2015) 4, e001469- PubMed  Europe PubMed DOI  I
  8. Gilibili,R.R., Bhamidipati,R.K., Mullangi,R. and Srinivas,N.R.
    Retrospective and prospective human intravenous and oral pharmacokinetic projection of dipeptidyl peptidase-IV inhibitors using simple allometric principles - case studies of ABT-279, ABT-341, alogliptin, carmegliptin, sitagliptin and vildagliptin
    J Pharm Pharm Sci (2015) 18, 434-448. PubMed  Europe PubMed  I
  9. Keating,G.M.
    Alogliptin: a review of its use in patients with type 2 diabetes mellitus
    Drugs (2015) 75, 777-796. PubMed  Europe PubMed DOI  I
  10. Marino,A.B. and Cole,S.W.
    Alogliptin: safety, efficacy, and clinical implications
    J Pharm Pract (2015) 28, 99-106. PubMed  Europe PubMed DOI  I
  11. Saisho,Y.
    Alogliptin benzoate for management of type 2 diabetes
    Vasc Health Risk Manag (2015) 11, 229-243. PubMed  Europe PubMed DOI  PMC  EPMC  I
  12. Scheen,A.J.
    Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes
    Expert Opin Drug Saf (2015) 14, 505-524. PubMed  Europe PubMed DOI  I
  13. Yamamoto,T., Shimano,M., Inden,Y., Takefuji,M., Yanagisawa,S., Yoshida,N., Tsuji,Y., Hirai,M. and Murohara,T.
    Alogliptin, a dipeptidyl peptidase-4 inhibitor, regulates the atrial arrhythmogenic substrate in rabbits
    Heart Rhythm (2015) 12, 1362-1369. PubMed  Europe PubMed DOI  I
    14. 2014
  14. Inagaki,N., Ueki,K., Tanizawa,Y., Watada,H., Nakamura,J., Yamada,Y., Shimomura,I., Nishimura,R., Yamazaki,T. and Kadowaki,T.
    Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry
    BMJ Open (2014) 4, e004760-e004760. PubMed  Europe PubMed DOI  PMC  EPMC  I
  15. Ndefo,U.A., Okoli,O. and Erowele,G.
    Alogliptin: a new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus
    Am J Health Syst Pharm (2014) 71, 103-109. PubMed  Europe PubMed DOI  I
  16. Said,S., Nwosu,A.C., Mukherjee,D. and Hernandez,G.T.
    Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus
    Cardiovasc Hematol Disord Drug Targets (2014) 14, 64-70. PubMed  Europe PubMed  I
  17. Seino,Y. and Yabe,D.
    Alogliptin benzoate for the treatment of type 2 diabetes
    Expert Opin Pharmacother (2014) 15, 851-863. PubMed  Europe PubMed DOI  I
    18. 2013
  18. Berhan,A. and Berhan,Y.
    Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies
    BMC Endocr Disord (2013) 13, 9-9. PubMed  Europe PubMed DOI  I
  19. Capuano,A., Sportiello,L., Maiorino,M.I., Rossi,F., Giugliano,D. and Esposito,K.
    Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy - focus on alogliptin
    Drug Des Devel Ther (2013) 7, 989-1001. PubMed  Europe PubMed DOI  PMC  EPMC  I
  20. Jarvis,C.I., Cabrera,A. and Charron,D.
    Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus
    Ann Pharmacother (2013) 47, 1532-1539. PubMed  Europe PubMed DOI  I
  21. Jurczyk,A., Diiorio,P., Brostowin,D., Leehy,L., Yang,C., Urano,F., Harlan,D.M., Shultz,L.D., Greiner,D.L. and Bortell,R.
    Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2rgamma(null) mice treated with alogliptin
    Diabetes Metab Syndr Obes (2013) 6, 493-499. PubMed  Europe PubMed DOI  PMC  EPMC  I
  22. Nabeno,M., Akahoshi,F., Kishida,H., Miyaguchi,I., Tanaka,Y., Ishii,S. and Kadowaki,T.
    A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site
    Biochem Biophys Res Commun (2013) 434, 191-196. PubMed  Europe PubMed DOI  I
  23. Teramachi,H., Ohta,H., Tachi,T., Toyoshima,M., Mizui,T., Goto,C. and Tsuchiya,T.
    Pharmacoeconomic analysis of DPP-4 inhibitors
    Pharmazie (2013) 68, 909-915. PubMed  Europe PubMed DOI  I
  24. White,W.B., Pratley,R., Fleck,P., Munsaka,M., Hisada,M., Wilson,C. and Menon,V.
    Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus
    Diabetes Obes Metab (2013) 15, 668-673. PubMed  Europe PubMed DOI  I
  25. Xie,H., Zeng,L., Zeng,S., Lu,X., Zhao,X., Zhang,G., Tu,Z., Xu,H., Yang,L., Zhang,X., Wang,S. and Hu,W.
    Highly potent dipeptidyl peptidase IV inhibitors derived from alogliptin through pharmacophore hybridization and lead optimization
    Eur J Med Chem (2013) 68, 312-320. PubMed  Europe PubMed DOI  I
    26. 2012
  26. Agrawal,R., Bahare,R.S., Jain,P., Dikshit,S.N. and Ganguly,S.
    Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin
    Mini Rev Med Chem (2012) 12, 1345-1358. PubMed  Europe PubMed DOI  I
  27. Gibbs,J.P., Fredrickson,J., Barbee,T., Correa,I., Smith,B., Lin,S.L. and Gibbs,M.A.
    Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results
    J Clin Pharmacol (2012) 52, 1494-1505. PubMed  Europe PubMed DOI  I
  28. Golightly,L.K., Drayna,C.C. and McDermott,M.T.
    Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors
    Clin Pharmacokinet (2012) 51, 501-514. PubMed  Europe PubMed DOI  I
  29. Monami,M., Lamanna,C., Desideri,C.M. and Mannucci,E.
    DPP-4 Inhibitors and lipids: systematic review and meta-analysis
    Adv Ther (2012) 29, 14-25. PubMed  Europe PubMed DOI  I
  30. Rendell,M., Drincic,A. and Andukuri,R.
    Alogliptin benzoate for the treatment of type 2 diabetes
    Expert Opin Pharmacother (2012) 13, 553-563. PubMed  Europe PubMed DOI  I
    31. 2011
  31. Baetta,R. and Corsini,A.
    Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences
    Drugs (2011) 71, 1441-1467. PubMed  Europe PubMed DOI  I
  32. Davidson,E.P., Coppey,L.J., Dake,B. and Yorek,M.A.
    Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications
    Exp Diabetes Res (2011) 2011, 810469-810469. PubMed  Europe PubMed DOI  PMC  EPMC  I
  33. Gupta,V. and Kalra,S.
    Choosing a gliptin
    Indian J Endocrinol Metab (2011) 15, 298-308. PubMed  Europe PubMed DOI  PMC  EPMC  I
  34. Kalra,S., Unnikrishnan,A.G., Agrawal,N. and Singh,A.K.
    Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications
    Recent Pat Endocr Metab Immune Drug Discov (2011) 5, 197-202. PubMed  Europe PubMed DOI  I
  35. Parsa,K.V.L. and Pal,M.
    Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview
    Expert Opin Drug Discov (2011) 6, 855-869. PubMed  Europe PubMed DOI  V  I
  36. Richard,K.R., Shelburne,J.S. and Kirk,J.K.
    Tolerability of dipeptidyl peptidase-4 inhibitors: a review
    Clin Ther (2011) 33, 1609-1629. PubMed  Europe PubMed DOI  V  I
  37. Shah,Z., Kampfrath,T., Deiuliis,J.A., Zhong,J., Pineda,C., Ying,Z., Xu,X., Lu,B., Moffatt-Bruce,S., Durairaj,R., Sun,Q., Mihai,G., Maiseyeu,A. and Rajagopalan,S.
    Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis
    Circulation (2011) 124, 2338-2349. PubMed  Europe PubMed DOI  I
  38. Ta,N.N., Schuyler,C.A., Li,Y., Lopes-Virella,M.F. and Huang,Y.
    DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice
    J Cardiovasc Pharmacol (2011) 58, 157-166. PubMed  Europe PubMed DOI  I
  39. White,J.R.
    Alogliptin for the treatment of type 2 diabetes
    Drugs Today (Barc) (2011) 47, 99-107. PubMed  Europe PubMed DOI  I
    40. 2010
  40. Ghatak,S.B., Patel,D.S., Shanker,N., Srivstava,A., Deshpande,S.S. and Panchal,S.J.
    Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus
    Curr Diabetes Rev (2010) 6, 410-421. PubMed  Europe PubMed  I
  41. Moritoh,Y., Takeuchi,K. and Hazama,M.
    Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice
    Diabetes Obes Metab (2010) 12, 224-233. PubMed  Europe PubMed DOI  I
  42. Scott,L.J.
    Alogliptin: a review of its use in the management of type 2 diabetes mellitus
    Drugs (2010) 70, 2051-2072. PubMed  Europe PubMed DOI  I
    43. 2009
  43. Argyrakopoulou,G. and Doupis,J.
    DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy
    Adv Ther (2009) 26, 272-280. PubMed  Europe PubMed DOI  I
  44. Asakawa,T., Moritoh,Y., Kataoka,O., Suzuki,N., Takeuchi,K. and Odaka,H.
    A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure
    Life Sci (2009) 85, 122-126. PubMed  Europe PubMed DOI  I
  45. Christopher,R. and Karim,A.
    Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes
    Expert Rev Clin Pharmacol (2009) 2, 589-600. PubMed  Europe PubMed DOI  I
  46. Karim,A., Laurent,A., Munsaka,M., Wann,E., Fleck,P. and Mekki,Q.
    Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants
    J Clin Pharmacol (2009) 49, 1210-1219. PubMed  Europe PubMed DOI  I
  47. Moritoh,Y., Takeuchi,K., Asakawa,T., Kataoka,O. and Odaka,H.
    Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice
    Br J Pharmacol (2009) 157, 415-426. PubMed  Europe PubMed DOI  PMC  EPMC  I
  48. Moritoh,Y., Takeuchi,K., Asakawa,T., Kataoka,O. and Odaka,H.
    The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice
    Eur J Pharmacol (2009) 602, 448-454. PubMed  Europe PubMed DOI  I
  49. Nauck,M.A., Ellis,G.C., Fleck,P.R., Wilson,C.A. and Mekki,Q.
    Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A multicentre, randomised, double-blind, placebo-controlled study
    Int J Clin Pract (2009) 63, 46-55. PubMed  Europe PubMed DOI  I
  50. Pratley,R.E.
    Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
    Expert Opin Pharmacother (2009) 10, 503-512. PubMed  Europe PubMed DOI  I
  51. Pratley,R.E., McCall,T., Fleck,P.R., Wilson,C.A. and Mekki,Q.
    Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies
    J Am Geriatr Soc (2009) 57, 2011-2019. PubMed  Europe PubMed DOI  I
  52. Pratley,R.E., Kipnes,M.S., Fleck,P.R., Wilson,C. and Mekki,Q.
    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
    Diabetes Obes Metab (2009) 11, 167-176. PubMed  Europe PubMed DOI  I
  53. Pratley,R.E., Reusch,J.E., Fleck,P.R., Wilson,C.A. and Mekki,Q.
    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
    Curr Med Res Opin (2009) 25, 2361-2371. PubMed  Europe PubMed DOI  I
    54. 2008
  54. Christopher,R., Covington,P., Davenport,M., Fleck,P., Mekki,Q.A., Wann,E.R. and Karim,A.
    Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects
    Clin Ther (2008) 30, 513-527. PubMed  Europe PubMed DOI  I
  55. Covington,P., Christopher,R., Davenport,M., Fleck,P., Mekki,Q.A., Wann,E.R. and Karim,A.
    Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
    Clin Ther (2008) 30, 499-512. PubMed  Europe PubMed DOI  I
  56. Deacon,C.F.
    Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes
    Curr Opin Investig Drugs (2008) 9, 402-413. PubMed  Europe PubMed  I
  57. Defronzo,R.A., Fleck,P.R., Wilson,C.A. and Mekki,Q.
    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with Type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study
    Diabetes Care (2008) 31, 2315-2317. PubMed  Europe PubMed DOI  PMC  EPMC  I
  58. Feng,J., Zhang,Z., Wallace,M.B., Stafford,J.A., Kaldor,S.W., Kassel,D.B., Navre,M., Shi,L., Skene,R.J., Asakawa,T., Takeuchi,K., Xu,R., Webb,D.R. and Gwaltney II,S.L.
    Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV (Journal of Medicinal Chemistry (2007) 50, (2297-2300))
    J Med Chem (2008) 51, 4357-4357. DOI  I
  59. Lee,B., Shi,L., Kassel,D.B., Asakawa,T., Takeuchi,K. and Christopher,R.J.
    Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys
    Eur J Pharmacol (2008) 589, 306-314. PubMed  Europe PubMed DOI  I
  60. Moritoh,Y., Takeuchi,K., Asakawa,T., Kataoka,O. and Odaka,H.
    Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice
    Eur J Pharmacol (2008) 588, 325-332. PubMed  Europe PubMed DOI  I
  61. Wang,Y., Serradell,N., Rosa,E. and Bolos,J.
    Alogliptin benzoate. Dipeptidyl-peptidase IV (DPP IV) inhibitor treatment of type 2 diabetes
    Drugs Future (2008) 33, 7-12. DOI  I
    62. 2007
  62. Feng,J., Zhang,Z., Wallace,M.B., Stafford,J.A., Kaldor,S.W., Kassel,D.B., Navre,M., Shi,L., Skene,R.J., Asakawa,T., Takeuchi,K., Xu,R., Webb,D.R. and Gwaltney,S.L.
    Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV
    J Med Chem (2007) 50, 2297-2300. PubMed  Europe PubMed DOI  I

feedback
Page created 8-September-2023

EMBL-EBI logo

© 2026 EBI
Terms of use